Type 2 Diabetes Mellitus
Conditions
Keywords
Vitamin D fortification, Yogurt Drink, Efficacy
Brief summary
Study is a 12-week Double blind,controlled experiments designed to examine the possible effects of vitamin D receptor gene polymorphisms on the metabolic, inflammatory and oxidative stress markers in type 2 diabetic patients to vitamin D-fortified yogurt drink intake.
Detailed description
In a 12-week randomized controlled trial ( double-blind study), based on data on serum 25(OH)D changes from other studies (35), to achieve 1 standard deviation difference in circulating 25(OH)D with two-sided alpha of 0.05 and a beta of 0.2 after a 12-week intervention period, the sample size was calculated 40 individuals per treatment group. Considering 3 polymorphic variant groups and one control group which receives plain yogurt drink, 160 subjects are needed. Allowing for 10% attrition over 12 weeks of intervention, a total of 180 subjects are required. In treatment groups, all patients receive 500 ml per day of low-fat (1%) Yogurt Drink fortified with approximately 500IU of vitamin D3 . Control group receives 500 ml per day of plain (unfortified) Yogurt Drink. Metabolic, inflammatory and oxidative stress markers are evaluated at the beginning and in the end of the interventional period.
Interventions
Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
Daily intake of unfortified yogurt drink(500 ml)for 12 weeks
Sponsors
Study design
Eligibility
Inclusion criteria
* Type 2 diabetes * Informed consent * BMI between 25 to 35 kg/m2 * Age: 30-45 years old * Willingness to maintain current body weight for the duration of the study * Willingness to maintain baseline lifestyle activities and routines for the duration of the study * Willingness to avoid the use of all over-the-counter or prescription vitamins, dietary supplements, and herbal products during the study
Exclusion criteria
* History of cardiovascular , Gastrointestinal , Renal disease and any other endocrinological disorders * Subjects receiving vitamin D or omega-3 supplement * Pregnancy , or lactation within the study period * Treatment with insulin * Treatment for weight reduction * Treatment for reducing serum lipids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum 25-hydroxyvitamin D | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure | 3 Months |
| Glycemic control | 3 Months |
| Inflammatory markers | 3 Months |
| Oxidative stress markers | 3 Months |
| Lipid profiles | 3 Months |
Countries
Iran